Strategic Acquisition 360biolabs operates as part of the BioAgilytix family after a recent acquisition, signaling potential cross-sell opportunities for BioAgilytix’s broader contract research capabilities and global reach in large molecule development.

Global Lab Network With GLP, GCP, ISO17025 compliant operations and labs in Australia, US, and Europe, there is strong potential to offer multi-region study support, method transfer, and cross-border PK/PD services to pharma partners expanding internationally.

Phase I-III Focus Specialization in Phase I-III clinical studies and a broad assay portfolio (PK, PD, LC/MS, Flow Cytometry, Biomarkers, Virology) positions an opportunity to upsell integrated analytical solutions and central laboratory services for late-stage programs.

Quality and Compliance Emphasis on ICH, FDA, EMA compliance and robust QA systems suggests a value proposition around risk mitigation, data integrity, and accelerated study timelines that resonates with sponsors aiming to de-risk trials.

Growth Potential with Partners Recent partnerships and affiliations in Australia and New Zealand, plus ties to global CROs, indicate a fertile landscape for expansion through joint proposals, bundled services, and long-term outsourcing agreements.